Monitoring Changes in Blood Circulating Metabolites Using Minimally Invasive Techniques

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorÖrebro University, Sweden

About this trial

This study investigates short-term intra- and inter-individual variability in human blood metabolism under real-life conditions. Using minimally invasive finger-prick blood sampling, dietary records, and wearable devices, we will longitudinally monitor blood-circulating metabolites and glucose levels in healthy individuals over a four-week period without dietary or lifestyle intervention. The study focuses on metabolic transitions between pre- and postprandial states during habitual daily activities and routine meals. Mass spectrometry-based metabolomics will be used to characterize metabolite profiles and their associations with diet, physical activity, sleep, and stress. In parallel, the study evaluates the feasibility of microsampling approaches, wearable-derived physiological data, and isotope-labelled standards for robust and cost-effective metabolite quantification. The results will inform the design of larger longitudinal studies using minimally invasive blood sampling in non-controlled settings.

Eligibility criteria

Qualifiers

Age: 18-65 years old

Body Mass Index (BMI): 18.5-29.9 kg/m2

Weight stability within the previous 3 months (self-reported).

Positive intention to maintain usual routine physical activity and eating habits during the study.

Disqualifiers

Presence of acute chronic diseases, inflammatory or functional gastrointestinal disorders, or any diagnosed disease condition that disrupt daily routine activities.

Routine use medications or supplements that could potentially interfere with the study outcomes

History of eating disorder

Recent use of antibiotic medication within the last 3 months prior to the first visit

Trial design

Treatments tested in this trial

  • Burger
  • Daily blood microsampling
  • Daily glucose monitoring

Treatment groups

35 Participants
are divided into 1 treatment group

Sponsors and collaborators